首页> 外文期刊>Bone marrow transplantation >Combined positive and negative cell selection from allogeneic peripheral blood progenitor cells (PBPC) by use of immunomagnetic methods.
【24h】

Combined positive and negative cell selection from allogeneic peripheral blood progenitor cells (PBPC) by use of immunomagnetic methods.

机译:通过免疫磁方法从同种异体外周血祖细胞(PBPC)中进行阳性和阴性细胞联合选择。

获取原文
获取原文并翻译 | 示例
           

摘要

Twenty-four mobilized peripheral blood products from healthy donors for allogeneic transplantation were positively selected for CD34(+) cells and depleted of CD4(+) and CD8(+) cells (+/- selection) by combining clinical grade immunomagnetic methods. A sequential, "two-step" strategy combining positive selection of CD34(+) cells by use of the Isolex 300i (versions 1 and 2) device and T cell depletion (TCD) using the MaxSep device and a simultaneous, "one-step" method of CD34(+)cell selection and TCD using the Isolex 300i (software versions 1 and 2) have been investigated. Using these magnetic bead separation systems, two groups of sequential +/- selection (Isolex 300i version 1/MaxSep and Isolex 300i version 2/MaxSep) and two groups of simultaneous +/- selection (Isolex 300i versions 1 and 2) were analysed. In the sequential +/- selection, logarithms of TCD (CD3(+) cell depletion) obtained by the positive selection step had median values of 3.7 with the version 1 (n = 5) and 4.5 with version 2 software of the Isolex 300i (n = 5) (P = 0.07). Version 2 also gave a higher CD34(+) cell purity and yield than did version 1 (92% vs77%, P < 0.05 and 55% vs 34%, P = 0.3, respectively). Additional TCD obtained in the second step with the MaxSep device for the two groups had a median value of 0.9 log and 7% CD34(+)cell losses. In the simultaneous +/- selection, the Isolex 300i version 2 (n = 10) gave a median TCD of 5.1 log and version 1 (n = 4) of 4 log (P < 0.005). Higher CD34(+)cell purity and yield were also obtained with version 2 than with version 1 (97% and 76%, P < 0.005 and 57% and 39%, P = 0.07, respectively). These data indicate that simultaneous, "one-step" +/- selection in the Isolex 300i version 2 achieves a high TCD with a high CD34(+) cell purity and an acceptable CD34(+) cell yield.
机译:结合临床级别的免疫磁方法,从CD34(+)细胞中积极选择了来自健康供体的二十四种动员外周血产品进行同种异体移植,并去除了CD4(+)和CD8(+)细胞(+/-选择)。一种顺序的“两步”策略,结合使用Isolex 300i(版本1和2)设备和使用MaxSep设备的T细胞耗竭(TCD)对CD34(+)细胞进行阳性选择,以及同时进行的“一步”研究了使用Isolex 300i(软件版本1和2)的CD34(+)细胞选择和TCD方法。使用这些磁珠分离系统,分析了两组顺序的+/-选择(Isolex 300i版本1 / MaxSep和Isolex 300i版本2 / MaxSep)和两组同时的+/-选择(Isolex 300i版本1和2)。在顺序+/-选择中,通过正选择步骤获得的TCD(CD3(+)细胞耗竭)的对数的中间值在Isolex 300i的版本1(n = 5)和版本2的软件中值为4.5( n = 5)(P = 0.07)。与版本1相比,版本2还具有更高的CD34(+)细胞纯度和产量(分别为92%vs77%,P <0.05和55%vs 34%,P = 0.3)。在第二步中,使用MaxSep装置获得的另外两组TCD的中值为0.9 log,CD34(+)细胞损失为7%。在同时+/-选择中,Isolex 300i版本2(n = 10)的中位数TCD为5.1 log,版本1(n = 4)的中位数为4 log(P <0.005)。与版本1相比,版本2还获得了更高的CD34(+)细胞纯度和产率(分别为97%和76%,P <0.005和57%和39%,P = 0.07)。这些数据表明,Isolex 300i版本2中同时进行的“单步” +/-选择可实现具有高CD34(+)细胞纯度和可接受的CD34(+)细胞产量的高TCD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号